目的 探討?zhàn)B心生脈顆粒聯(lián)合非洛地平緩釋片治療冠心病心絞痛的臨床療效。方法 選取2017年4月—2018年4月在大連市第三人民醫(yī)院治療的冠心病心絞痛患者96例，根據(jù)用藥的差別分為對(duì)照組（48例）和治療組（48例）。對(duì)照組口服非洛地平緩釋片，初始劑量為5 mg/次，1次/d，根據(jù)病情可減至2.5 mg/次，或增至10 mg/次，調(diào)整劑量間隔時(shí)間≥2周。治療組在對(duì)照組治療基礎(chǔ)上口服養(yǎng)心生脈顆粒，14 g/次，3次/d。兩組患者均治療12周。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者心絞痛發(fā)作次數(shù)和持續(xù)時(shí)間以血清學(xué)、血液流變學(xué)和心功能指標(biāo)。結(jié)果 治療后，對(duì)照組和治療組臨床有效率分別為81.25%和97.92%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組心絞痛發(fā)作次數(shù)及持續(xù)時(shí)間均顯著減少（P<0.05），且治療組心絞痛發(fā)作次數(shù)和持續(xù)時(shí)間明顯低于對(duì)照組（P<0.05）。治療后，兩組白細(xì)胞介素-1β（IL-1β）、可溶性細(xì)胞間黏附分子1（sICAM-1）、核轉(zhuǎn)錄因子-κB（NF-κB）、基質(zhì)金屬蛋白酶-9（MMP-9）、全血黏度（WBV）、血漿黏度（PV）、纖維蛋白原（FIB）和血小板黏附率（PAR）水平均顯著降低（P<0.05），且治療組這些指標(biāo)水平明顯低于對(duì)照組（P<0.05）。治療后，兩組左心室射血分?jǐn)?shù)（LVEF）和心輸出量（CO）均顯著升高（P<0.05），左心室收縮末期內(nèi)徑（LVESD）顯著降低（P<0.05），且治療組心功能明顯好于對(duì)照組（P<0.05）。結(jié)論 養(yǎng)心生脈顆粒聯(lián)合非洛地平緩釋片治療冠心病心絞痛可有效降低心絞痛發(fā)作次數(shù)，降低機(jī)體炎癥因子水平，促進(jìn)血液流變學(xué)指標(biāo)和心功能改善。

Objective To explore the clinical effect of Yangxin Shengmai Granules combined with Felodipine in treatment of angina pectoris of coronary heart disease. Methods Patients (96 cases) with angina pectoris of coronary heart disease in the Third People's Hospital of Dalian from April 2017 to April 2018 were divided into control (48 cases) and treatment (48 cases) groups according to different treatments. Patients in the control group were po administered with Felodipine Sustained Release Tablets, and the initial dose was 5 mg/time, once daily. The dose can be reduced to 2.5 mg/time or increased to 10 mg/time according to the patient's condition, the interval time of adjusting dose ≥ 2 weeks. Patients in the treatment group were po administered with Yangxin Shengmai Granules on the basis of the control group, 14 g/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the frequency and duration of angina pectoris, serological, hemorheological and cardiac function indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 81.25% and 97.92% respectively, and there were differences between two groups (P<0.05). After treatment, the frequency and duration of angina pectoris in two groups was significantly decreased (P<0.05), which in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the IL-1β, sICAM-1, NF-κB, MMP-9, WBV, PV, FIB and PAR levels in two groups were significantly decreased (P<0.05), and these indexes in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the LVEF and CO in two groups were significantly increased (P<0.05), but LVESD was significantly increased (P<0.05), and the cardiac function indexes in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Yangxin Shengmai Granules combined with Felodipine in treatment of angina pectoris of coronary heart disease can effectively reduce the frequency of angina pectoris, the level of inflammatory factors, improve the hemorheological indexes and the heart function.